Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models
The incidence of empyema (EMP) is increasing worldwide, generally occurs with pleural loculation and impaired drainage is often treated with intrapleural fibrinolytic therapy (IPFT) or surgery. A number of IPFT options are used clinically with empiric dosing and variable outcomes in adults. To evalu...
Egile Nagusiak: | Komissarov, A, Florova, G, Azghani, A, Buchanan, A, Boren, J, Allen, T, Rahman, N, Koenig, K, Chamiso, M, Karandashova, S, Henry, J, Idell, S |
---|---|
Formatua: | Journal article |
Hizkuntza: | English |
Argitaratua: |
American Physiological Society
2016
|
Antzeko izenburuak
-
Precision-guided, personalized intrapleural fibrinolytic therapy for empyema and complicated parapneumonic pleural effusions: The case for the fibrinolytic potential
nork: Idell, S, et al.
Argitaratua: (2017) -
Intrapleural fibrinolytic therapy for empyema and pleural loculation: knowns and unknowns
nork: Idell, S, et al.
Argitaratua: (2018) -
Intrapleural and plasma processing of LTI-01 (single chain urokinase Plasminogen Activator, scuPA) in a phase 1b trial of LTI-01 Intrapleural Fibrinolytic Therapy (IPFT) in patients with Complicated Parapneumonic Effusions (CPE) or empyema
nork: Komissarov, A, et al.
Argitaratua: (2019) -
Phase 1b Trial of LTI-01 (Single Chain Urokinase Plasminogen Activator, scuPA) Intrapleural Fibrinolytic Therapy (IPFT) in Patients with Complicated Parapneumonic Effusions (CPE) or Empyema
nork: Idell, S, et al.
Argitaratua: (2019) -
Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema
nork: Beckert, L, et al.
Argitaratua: (2019)